Clinical trials: Intestinal Fibrosis
Cystic Fibrosis, Inflammatory Bowel Disease
MD2Me - Texting to Promote Chronic Disease Management
UCSD researchers are conducting a study aimed to develop and evaluate a chronic disease self management web and text message based program on health-related self-efficacy and frequency of adolescent-conducted healthcare…
- Conditions
- Cystic Fibrosis, Inflammatory Bowel Disease, Type 1 Diabetes, Chronic Disease Management
- Trial name
- NCT01253733
- Testing
- MD2ME
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Huang, Jeannie, M.D.
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Cystic Fibrosis
Organoid Study R334W
In contrary to what is seen in FRT cells, rectal organoids of patients with a R334W mutation do respond to CFTR modulators ivacaftor and lumacaftor.
- Trial name
- NCT04254705
- Testing
- Rectal Biopsy
- Where
- 12 sites in Belgium, France and 3 more
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cystic Fibrosis
Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor
Cystic fibrosis is a systemic disease, which affects in particular the respiratory and digestive systems of patients, sites of chronic inflammation.
- Trial name
- KAF-BIOTA (NCT05937815)
- Testing
- Sample collection
- Where
- 15 sites in France
- Volunteers
- 253 people
- Sponsor
- University Hospital, Bordeaux
Cystic Fibrosis, Gastrointestinal Dysfunction
Understanding Gut Symptoms in People With Cystic Fibrosis
Although chest infections affect wellbeing and survival in cystic fibrosis (CF), most people with CF also have difficulty digesting food and must take medication for this.
- Trial name
- GRAMPUS-CF SRC (NCT05934656)
- Testing
- Latent class analysis
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- University of Nottingham
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
This study by Aptalis (formerly Axcan) assesses the efficacy and safety of Panzytrat® 25,000 compared to Kreon® 25,000 in the control of steatorrhea in participants with cystic fibrosis (CF) and exocrine pancreatic insufficiency…
- Trial name
- NCT01327703
- Testing
- Panzytrat® 25,000, Kreon® 25,000
- Where
- 13 sites in Germany, Poland
- Volunteers
- 87 people
- Sponsor
- Forest Laboratories
Cystic Fibrosis, Digestive System Disease
A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF
Development of a new patient reported outcome measure (PROM) that will measure the daily burden of gastrointestinal symptoms over the previous 24 hour period for people with cystic fibrosis.
- Conditions
- Cystic Fibrosis, Digestive System Disease, Genetic Disease, Respiratory Tract Diseases
- Trial name
- CARDS-CF (NCT05251467)
- Testing
- Focus group, Patient interview (n = approximately 10), Questionnaire (n = 180)
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cystic Fibrosis, Pancreatic Insufficiency
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
The primary objective of this study is to determine if PANCRECARB® MS-16 (pancrelipase) is safe and effective in reducing steatorrhea (as measured by 72-hour stool fat determinations) in children and adults with cystic fibrosis…
- Trial name
- NCT00432861
- Testing
- PANCRECARB® (pancrelipase)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Digestive Care, Inc.
Cystic Fibrosis
Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis
The main objective of the study is to evaluate the effectiveness of polyethylene glycol treatment on intestinal inflammation in children with cystic fibrosis.
- Trial name
- MUCOLAX (NCT04458129)
- Testing
- Treatment with polyethylene glycol (Macrogol 4000)
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
NPDT Evaluation in Children With CFTR and (PSC)
The investigators hypothesize that PSC in children is associated with mutations and functional changes of the cystic fibrosis (CF) gene.
- Trial name
- NPD (NCT00179439)
- Testing
- nasal potential difference testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cystic Fibrosis
Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
People with Cystic Fibrosis (CF) have problems digesting their food properly. More than 8 in 10 people with CF must take medication to assist their digestion. In spite of this, complications such as bowel blockage occur.
- Trial name
- GIFT-CF2 (NCT04006873)
- Testing
- Tezacaftor/Ivacaftor + Ivacaftor
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cystic Fibrosis in Children, Cystic Fibrosis Gastrointestinal Disease
Intestinal Inflammation in CF Patients
Cystic Fibrosis (CF) is a disease that affects salt and water transport in multiple organs. Many CF patients suffer from abdominal pain and this could be due to intestinal inflammation.
- Conditions
- Cystic Fibrosis in Children, Cystic Fibrosis Gastrointestinal Disease, Cystic Fibrosis
- Trial name
- NCT04392544
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- The Hospital for Sick Children
Chronic Nasal Congestion, Lung Infection
Biomarker for Cystic Fibrosis
International, multicenter, observational, longitudinal study to identify biomarker/s for Cystic fibrosis and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s
- Conditions
- Chronic Nasal Congestion, Lung Infection, Breathlessness, Clubbing Toes
- Trial name
- BioCyFi (NCT02710383)
- Where
- 5 sites in Albania, Georgia and 3 more
- Volunteers
- 54 people
- Sponsor
- CENTOGENE GmbH Rostock
Cystic Fibrosis, Lung Disease
Benefits and Risks of Newborn Screening for Cystic Fibrosis
Although cystic fibrosis (CF) is the most common, life-threatening autosomal recessive genetic disorder of the white population, there are often delays in diagnosis and hence start of treatment.
- Conditions
- Cystic Fibrosis, Lung Disease, Pseudomonas Infections
- Trial name
- NCT00014950
- Testing
- CF newborn screening
- Where
- 2 sites in United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cystic Fibrosis, Abdominal Pain
Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis
Gastrointestinal symptoms are commonly reported in as much as 65% of people with CF even independent of pancreatic enzyme replacement therapy (PERT) and the most frequent of these symptoms are bloating/distension, flatulence…
- Conditions
- Cystic Fibrosis, Abdominal Pain, Small Bowel Disease
- Trial name
- NCT05408910
- Testing
- Rifaximin 550 MG Oral Tablet [XIFAXAN]
- Sponsor
- Wake Forest University Health Sciences
Hepatic Disorders, Intestinal Failure-associated Liver Disease
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
The goal of this observational (diagnostic validation) study is to validate imaging-based biomarkers for assessing liver involvement in pediatric patients with established or suspected liver disease.
- Conditions
- Hepatic Disorders, Intestinal Failure-associated Liver Disease, Cystic Fibrosis Liver Disease, MAFLD
- Trial name
- VALiBi-PED (NCT07202910)
- Where
- Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Cystic Fibrosis
Probiotics in Cystic Fibrosis
Cystic fibrosis (CF) is a complex systemic disease that mainly involves the respiratory and gastrointestinal (GI) tracts. The polymicrobial community composition of respiratory and GI tracts is influenced by both genetic and…
- Trial name
- NCT01956916
- Testing
- Lactobacillus rhamnosus GG
- Where
- 5 sites in Italy
- Volunteers
- 110 people
- Sponsor
- Federico II University
Small Bowel Obstruction
Early Small Bowel Obstruction Following Laparotomy For Trauma
The formation of intraperitoneal adhesion following abdominal surgery is accepted by clinicians as an inevitable consequence. More than 90% of patients undergoing a surgical procedure in the abdomen will develop intraperitoneal…
- Trial name
- NCT01068340
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- University of Southern California
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association